Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02443883
Title A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company

stomach cancer

gastroesophageal junction adenocarcinoma



Age Groups: adult
Covered Countries USA | FRA

No variant requirements are available.